🟢 Alcon is trading 4.01% up with no confirmed company-specific catalyst

Alcon is trading 4.01% up at $70.14 on October 22, 2026; no reliable report directly links the intraday gain to a new company announcement.

• The healthcare sector is up 1.35%, while major U.S. indexes are down.
• Alcon’s $550 million Neurotech acquisition, announced October 20, adds FDA-approved ENCELTO retinal therapy. It is expected to modestly boost net sales growth but slightly dilute 2027 core earnings per share; available reporting does not establish it as the cause of today’s move.